TY  - JOUR
AU  - Veljković, Nevena V.
AU  - Branch, DR
AU  - Metlaš, Radmila
AU  - Prljić, Jelena
AU  - Manfredi, R
AU  - Stringer, WW
AU  - Veljković, Veljko
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2837
AB  - It has been reported that antibodies reactive with peptide RSANFTDNAKTIIVQLNQSVEIN (peptide NTM) derived from the C-terminus of the second conserved domain of HIV-1 envelope glycoprotein gp120 could represent an important factor in control of the HIV disease. In order to check this notion we (i) tested reactivity with peptide NTM serum samples collected from 310 consecutive HIV-1 infected patients with a CD4(+) lymphocyte count ranging from 10 to 800/muL and (ii) performed the longitudinal study that included 107 sera samples collected from 29 HIV patients. Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count. Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease. (C) 2004 Elsevier B.V. All rights reserved.
T2  - Journal of Clinical Virology
T1  - Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease
VL  - 31
SP  - S39
EP  - S44
DO  - 10.1016/j.jcv.2004.09.012
ER  - 

@article{
author = "Veljković, Nevena V. and Branch, DR and Metlaš, Radmila and Prljić, Jelena and Manfredi, R and Stringer, WW and Veljković, Veljko",
year = "2004",
abstract = "It has been reported that antibodies reactive with peptide RSANFTDNAKTIIVQLNQSVEIN (peptide NTM) derived from the C-terminus of the second conserved domain of HIV-1 envelope glycoprotein gp120 could represent an important factor in control of the HIV disease. In order to check this notion we (i) tested reactivity with peptide NTM serum samples collected from 310 consecutive HIV-1 infected patients with a CD4(+) lymphocyte count ranging from 10 to 800/muL and (ii) performed the longitudinal study that included 107 sera samples collected from 29 HIV patients. Results of these studies demonstrated correlation between presence of anti-NTM antibodies in sera of HIV patients and disease progression measured by the CD4(+) cell count. Based on these findings we proposed the anti-NTM antibodies as useful prognostic marker for HIV disease. (C) 2004 Elsevier B.V. All rights reserved.",
journal = "Journal of Clinical Virology",
title = "Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease",
volume = "31",
pages = "S39-S44",
doi = "10.1016/j.jcv.2004.09.012"
}

Veljković, N. V., Branch, D., Metlaš, R., Prljić, J., Manfredi, R., Stringer, W.,& Veljković, V.. (2004). Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. in Journal of Clinical Virology, 31, S39-S44.
https://doi.org/10.1016/j.jcv.2004.09.012

Veljković NV, Branch D, Metlaš R, Prljić J, Manfredi R, Stringer W, Veljković V. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. in Journal of Clinical Virology. 2004;31:S39-S44.
doi:10.1016/j.jcv.2004.09.012 .

Veljković, Nevena V., Branch, DR, Metlaš, Radmila, Prljić, Jelena, Manfredi, R, Stringer, WW, Veljković, Veljko, "Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease" in Journal of Clinical Virology, 31 (2004):S39-S44,
https://doi.org/10.1016/j.jcv.2004.09.012 . .

TY  - JOUR
AU  - Veljković, Veljko
AU  - Metlaš, Radmila
AU  - Jevtović, D.
AU  - Stringer, WW
PY  - 2001
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2448
AB  - An HIV positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months). She received zidovudine for 6 weeks at the time of her diagnosis; however, because of patient preference, she has not received subsequent standard HIV medications (7 years). Her CD4 count at the time of diagnosis (1993) was 297/muL. Monthly passive immunotherapy was administered (fresh frozen plasma from HIV-negative blood donors with a significant titer for the anti-vasoactive intestinal peptide [VIP]/NTM antibody) from December 1993 to June 1994. Her CD4 count increased to GT 400/muL during the passive immunotherapy and has remained stable for the past 6 years. The rational for the use of anti-VIP/NTM antibodies preparations in HIV, the possible mode of action of anti-VIP/NTM antibodies, the use of Ig preparations, and the role of exercise as a natural source of anti-VIP/NTM antibodies are discussed. This case report supports the potential therapeutic use of anti-VIP antibodies for treatment of HIV disease.
T2  - Chest
T1  - The role of passive immunization in HIV-positive patients - A case report
VL  - 120
IS  - 2
SP  - 662
EP  - 666
DO  - 10.1378/chest.120.2.662
ER  - 

@article{
author = "Veljković, Veljko and Metlaš, Radmila and Jevtović, D. and Stringer, WW",
year = "2001",
abstract = "An HIV positive patient presented with pulmonary tuberculosis as her AIDS-defining diagnosis in 1993 and was effectively treated with 12 months of standard antituberculosis medications (isoniazide, rifampin, and pyrazinamide for 2 months). She received zidovudine for 6 weeks at the time of her diagnosis; however, because of patient preference, she has not received subsequent standard HIV medications (7 years). Her CD4 count at the time of diagnosis (1993) was 297/muL. Monthly passive immunotherapy was administered (fresh frozen plasma from HIV-negative blood donors with a significant titer for the anti-vasoactive intestinal peptide [VIP]/NTM antibody) from December 1993 to June 1994. Her CD4 count increased to GT 400/muL during the passive immunotherapy and has remained stable for the past 6 years. The rational for the use of anti-VIP/NTM antibodies preparations in HIV, the possible mode of action of anti-VIP/NTM antibodies, the use of Ig preparations, and the role of exercise as a natural source of anti-VIP/NTM antibodies are discussed. This case report supports the potential therapeutic use of anti-VIP antibodies for treatment of HIV disease.",
journal = "Chest",
title = "The role of passive immunization in HIV-positive patients - A case report",
volume = "120",
number = "2",
pages = "662-666",
doi = "10.1378/chest.120.2.662"
}

Veljković, V., Metlaš, R., Jevtović, D.,& Stringer, W.. (2001). The role of passive immunization in HIV-positive patients - A case report. in Chest, 120(2), 662-666.
https://doi.org/10.1378/chest.120.2.662

Veljković V, Metlaš R, Jevtović D, Stringer W. The role of passive immunization in HIV-positive patients - A case report. in Chest. 2001;120(2):662-666.
doi:10.1378/chest.120.2.662 .

Veljković, Veljko, Metlaš, Radmila, Jevtović, D., Stringer, WW, "The role of passive immunization in HIV-positive patients - A case report" in Chest, 120, no. 2 (2001):662-666,
https://doi.org/10.1378/chest.120.2.662 . .